drugset / Trial / NCT06584006
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors
Timeline
- Start
- 2024-09-01
- Primary completion
- 2027-11-30
- Completion
- 2028-02-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Human Interleukin-2 | Protein / enzyme biologic | 1e+06 iu | Subcutaneous |
| Subject | Thymalfasin | Peptide | 1.6 mg | Subcutaneous |